ADAM and Ephrin
Researchers target ADAM10 in lung fibrosis
An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by the receptor tyrosine kinase ephrin B2.
ADAM metallopeptidase domain 10 (ADAM10) is a “sheddase,” whose role is to cleave membrane proteins and release soluble ectodomains that regulate a range of cellular functions. Although it has been primarily explored for cancer, this report is the first to invoke a role for it in IPF...